

Platelet Function During Orthotopic Liver Transplantation. An observational study.

Published: 29-01-2008

Last updated: 11-05-2024

To establish platelet function during orthotopic liver transplantation.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Hepatic and hepatobiliary disorders
Study type	Observational invasive

Summary

ID

NL-OMON32329

Source

ToetsingOnline

Brief title

PLATO-II

Condition

- Hepatic and hepatobiliary disorders

Synonym

end-stage liver disease

Research involving

Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Groningen

Source(s) of monetary or material Support: Bayer,Bayer BV; Tekke Huizinga Fonds.

Intervention

Keyword: coagulation, orthotopic liver transplantation, platelet function, platelets

Outcome measures

Primary outcome

Development of functional properties of vWF during and after OLT.

Development of functional properties of platelets during and after OLT.

Circulation of partly activated platelets during OLT (especially after reperfusion).

Secondary outcome

Transfusion requirements, which contains all crystalloids, colloids and blood products as RBCs, FFPs and Trombocytes, during the operation.

Hepatic artery thrombosis.

total blood loss.

Study description

Background summary

Despite considerable progress in surgical techniques, orthotopic liver transplantation (OLT) is still associated with significant blood loss, resulting in requirement for transfusion of blood products in a substantial number of patients. Before surgery, patients have poorly characterized, multifactorial coagulopathic state, which aggravates perioperatively. One of the contributors to preoperative coagulopathy in patients eligible for OLT is a qualitative and quantitative blood platelet defect. Little is known, however, on the perioperative development of platelet function abnormalities.

Study objective

To establish platelet function during orthotopic liver transplantation.

Study design

observational clinical mono-center study.

Study burden and risks

Serial samples, containing blood samples and liver biopsies, will be studies during and after liver transplantation.

Blood samples: 4 times during surgery and 3 times (day 1,5 and 10) after surgery.

Liverbiopsies: following standard protocols. two times during surgery and one week after surgery.

The duration of the study per patient will not be longer than the admission time of the patient in the hospital. Patients who participate in the study do not have to come over for extra visits to the hospital.

Contacts

Public

Universitair Medisch Centrum Groningen

Hanzeplein 1
9713 GX Groningen
Nederland

Scientific

Universitair Medisch Centrum Groningen

Hanzeplein 1
9713 GX Groningen
Nederland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

age > 17 years

first liver transplantation for liver cirrhosis

retransplantation for liver cirrhosis, more than six months after previous OLT.

Exclusion criteria

age < 18 years

retransplantation within six months after first/last transplantation.

presence of metabolic disease

malignancies

Budd-chiari syndrome

portal vein thrombosis

use of aspirin 10 days before surgery.

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 01-01-2008

Enrollment: 20

Type: Anticipated

Ethics review

Approved WMO

Application type: First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL21105.042.07